Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Gilead Japan Looks to End HIV Pacts with JT as It Seeks Long-Term Growth: Chief
Gilead Sciences is looking to fill a “missing pillar” for its long-term growth in Japan by initiating talks with Japan Tobacco on the termination of their 15-year licensing collaboration in the HIV arena, country president Luc Hermans, M.D., told Jiho…
To read the full story
Related Article
- Gilead to Take Over MA for HIV Franchise from JT on Dec. 1
September 3, 2019
- Gilead Set to Duplicate Biktarvy Success in Japan with New Stand-Alone HIV Sales Force
March 20, 2019
- Gilead Files HIV Triplet Biktarvy in Japan, JT Pact Termination Set for Jan. 1
December 17, 2018
- JT to Return Rights to Gilead’s 6 HIV Agents in 2019, Get 63.1 Billion Yen
November 30, 2018
- Gilead, JT Start Talks on Terminating Japan HIV Pacts
August 27, 2018
BUSINESS
- Sumitomo Regains Growth Momentum, Eyes 350 Billion Yen from 2 Key Drugs in FY2028
March 3, 2026
- Middle East Turmoil Raises Fears over API Shipments as Key Airports Shut
March 3, 2026
- UCB, Daiichi Sankyo to Wind Up Japan Partnership for Vimpat
March 3, 2026
- Itochu Snaps Up CoreMed to Bolster Japan Entry Support
March 3, 2026
- Ono to Transfer Opalmon, Prostandin to Daito by November
March 3, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…